# EDGAR Filing Document

**Accession Number:** 0001906324
**File Stem:** 0001193125-25-151612
**Filing Date:** 2025-6
**Character Count:** 24576
**Document Hash:** 12fd9d56f567baf9a65ae77765505c68
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-25-151612.hdr.sgml**: 20250630

**ACCESSION NUMBER**: 0001193125-25-151612

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20250630

**DATE AS OF CHANGE**: 20250627

**EFFECTIVENESS DATE**: 20250630

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** QuidelOrtho Corp
- **CENTRAL INDEX KEY:** 0001906324
- **STANDARD INDUSTRIAL CLASSIFICATION:** IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 874496285
- **FISCAL YEAR END:** 0101

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-288409
- **FILM NUMBER:** 251088563

**BUSINESS ADDRESS:**
- **STREET 1:** 9975 SUMMERS RIDGE ROAD
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121
- **BUSINESS PHONE:** (858) 552-1100

**MAIL ADDRESS:**
- **STREET 1:** 9975 SUMMERS RIDGE ROAD
- **CITY:** SAN DIEGO
- **STATE:** CA
- **ZIP:** 92121

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Coronado Topco, Inc.
- **DATE OF NAME CHANGE:** 20220124

**As filed with the Securities and Exchange Commission on June 27, 2025** 

**Registration No. 333-** 

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**WASHINGTON, DC 20549** 

**FORM S-8** 

**REGISTRATION STATEMENT** 

***UNDER***

***THE SECURITIES ACT OF 1933***

## QUIDELORTHO CORPORATION
**(Exact name of registrant as specified in its charter)** 

---

| | |
|:---|:---|
| **Delaware** | **87-4496285** |
| **(State or Other Jurisdiction of<br>Incorporation or Organization)** | **(I.R.S. Employer<br>Identification No.)** |

---

**9975 Summers Ridge Road, San Diego, California 92121** 

**(Address of Principal Executive Offices, Zip Code)** 

**QuidelOrtho Corporation Second Amended and Restated 2018 Equity Incentive Plan** 

**(Full title of the plan)** 

**Michelle A. Hodges** 

**Chief Legal Officer** 

**9975 Summers Ridge Road** 

**San Diego, California 92121** 

**(858) 552-1100** 

**(Name, address, including zip code, and telephone number, including area code, of agent for service)** 

***With a copy to:***

**Sean C. Feller** 

**Gibson, Dunn & Crutcher LLP** 

**2000 Avenue of the Stars Suite 1200N** 

**Los Angeles, CA 90067-4700** 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

------

**EXPLANATORY NOTE** 

Pursuant to General Instruction E of Form S-8, QuidelOrtho Corporation (the "Registrant") is filing this registration statement on Form S-8 (this "Registration Statement") with respect to the issuance of an additional 6,200,000 shares of the Registrant's common stock, par value $0.001 per share ("Common Stock"), to be offered and sold under the QuidelOrtho Corporation Second Amended and Restated 2018 Equity Incentive Plan, as amended and restated effective May 20, 2025 (the "Equity Incentive Plan"). The contents of the Registration Statement on Form S-8 (File no. 333-265354) filed with the Securities and Exchange Commission (the "Commission") on [June 1, 2022](http://www.sec.gov/Archives/edgar/data/1906324/000119312522165312/d316175ds8.htm), with respect to the QuidelOrtho Corporation Amended and Restated 2018 Equity Incentive Plan (the "Original S-8") is hereby incorporated by reference in this Registration Statement pursuant to General Instruction E of Form S-8, except for Item 1 of Part I and Items 3, 8 and 9 of Part II, which are being updated by this Registration Statement.

**PART I** 

**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS** 

**Item 1.** **Plan Information.** <br>

The documents containing the information specified in Part I of Form S-8 will be delivered to participants in the Equity Incentive Plan as specified by Rule 428(b)(1) of the Securities Act of 1933, as amended (the "Securities Act"). In accordance with the instructions of Part I of Form S-8, such documents are not required to be and are not being filed with the Commission either as part of this Registration Statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. Such documents and the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II of Form S-8, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

**PART II** 

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT** 

**Item 3.** **Incorporation of Certain Documents by Reference.** <br>

The following documents, which have previously been filed by the Registrant with the Commission pursuant to the Securities Act and pursuant to the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are incorporated by reference herein and shall be deemed to be a part hereof:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the Registrant's Annual Report on Form 10-K for the fiscal year
ended December 29, 2024 filed with the Commission on [February 27, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001906324/000190632425000035/qdel-20241229.htm) ;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) the Registrant's Quarterly Report on Form 10-Q for the fiscal
quarter ended March 30, 2025 filed with the Commission on [May 8, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001906324/000190632425000057/qdel-20250330.htm) ;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) the Registrant's Current Reports on Form 8-K filed with the
Commission on [March 4, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001906324/000190632425000037/qdel-20250228.htm) and [May 27, 2025](http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/0001906324/000119312525127604/d908117d8k.htm) ; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) the description of the Company's securities under the caption "Description of TopCo Capital
Stock" contained in the Company's registration statement on Form S-4 filed with the Commission on [January 31, 2022](http://www.sec.gov/Archives/edgar/data/1906324/000119312522023500/d273090ds4.htm) , as updated from time to time by any amendment or report filed with the Commission for purposes of updating such description.

In addition, all documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (other than the portions of these documents furnished or not otherwise deemed to be filed), prior to the filing of a post-effective amendment to this Registration Statement which indicates that all securities offered hereby have been sold or which deregisters all securities remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents. Notwithstanding the foregoing, unless specifically stated to the contrary, none of the information that the Registrant discloses under Items 2.02 or 7.01 of any Current Report on Form 8-K that it may from time to time furnish to the Commission will be incorporated by reference into, or otherwise included in, this Registration Statement.

------

Any statement, including financial statements, contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or therein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 8.** **Exhibits.** <br>

The list of exhibits filed as part of this Registration Statement is included in the Exhibit Index which is incorporated by reference herein.

**Item 9.** **Undertakings.** <br>

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the provisions described in Item 6 set forth in the Original S-8, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

(a) The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the "Calculation of Registration Fee" table in the effective Registration Statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement;

&nbsp;&nbsp;&nbsp;&nbsp;*provided*, *however*, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference into the Registration Statement.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's Annual Report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference into the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

**EXHIBIT INDEX** 

---

| | |
|:---|:---|
| Exhibit<br> No. | Exhibit Description |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Amended and Restated Certificate of Incorporation of QuidelOrtho Corporation (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed on May 27, 2022).](http://www.sec.gov/Archives/edgar/data/0001906324/000119312522161806/d323352dex31.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Amended and Restated Bylaws of QuidelOrtho Corporation (incorporated by reference to Exhibit 3.1 to the Registrant's Current Report on Form 8-K filed on December 13, 2022).](http://www.sec.gov/Archives/edgar/data/1906324/000190632422000038/ex31amendedandrestatedbyla.htm) |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1\* | [Opinion of Gibson, Dunn & Crutcher LLP.](d936331dex51.htm) |
| 23.1\* | [Consent of Gibson, Dunn & Crutcher LLP (included in Exhibit 5.1).](d936331dex51.htm) |
| 23.2\* | [Consent of Independent Registered Public Accounting Firm.](d936331dex232.htm) |
| 24.1\* | [Power of Attorney (included on signature page).](d936331ds8.htm#sig) |
| 99.1 | [QuidelOrtho Corporation Second Amended and Restated 2018 Equity Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on May 27, 2025).](http://www.sec.gov/Archives/edgar/data/1906324/000119312525127604/d908117dex101.htm) |
| 107.1\* | [Filing Fee Table.](d936331dexfilingfees.htm) |

---

\* Filed herewith.

------

**SIGNATURES** 

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of San Diego, State of California, on June 27, 2025.

---

| | |
|:---|:---|
| QUIDELORTHO CORPORATION | QUIDELORTHO CORPORATION |
| By: | /s/ Brian J. Blaser |
| Name: | Brian J. Blaser |
| Title: | President and Chief Executive Officer |

---

**POWER OF ATTORNEY** 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints each of Brian J. Blaser, Joseph M. Busky and Michelle A. Hodges, and each of them acting individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in or about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitutes may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| /s/ Brian J. Blaser | President and Chief Executive Officer <br>(*Principal Executive Officer*) | June 27, 2025 |
| Brian J. Blaser | President and Chief Executive Officer <br>(*Principal Executive Officer*) |  |
| /s/ Joseph M. Busky | Chief Financial Officer <br>(*Principal Financial and Accounting Officer*) | June 27, 2025 |
| Joseph M. Busky | Chief Financial Officer <br>(*Principal Financial and Accounting Officer*) |  |
| /s/ Kenneth F. Buechler | Director | June 27, 2025 |
| Kenneth F. Buechler, Ph.D. | Director |  |
| /s/ John R. Chiminski | Director | June 27, 2025 |
| John R. Chiminski | Director |  |
| /s/ Evelyn S. Dilsaver | Director | June 27, 2025 |
| Evelyn S. Dilsaver | Director |  |
| /s/ R. Scott Huennekens | Director | June 27, 2025 |
| R. Scott Huennekens | Director |  |
| /s/ Edward L. Michael | Director | June 27, 2025 |
| Edward L. Michael | Director |  |

---

------

---

| | | |
|:---|:---|:---|
| /s/ Mary Lake Polan | Director | June 27, 2025 |
| Mary Lake Polan, M.D., Ph.D., M.P.H. | Director |  |
| /s/ Ann D. Rhoads | Director | June 27, 2025 |
| Ann D. Rhoads | Director |  |
| /s/ Matthew W. Strobeck | Director | June 27, 2025 |
| Matthew W. Strobeck, Ph.D. | Director |  |
| /s/ Kenneth J. Widder | Director | June 27, 2025 |
| Kenneth J. Widder, M.D. | Director |  |
| /s/ Joseph D. Wilkins | Director | June 27, 2025 |
| Joseph D. Wilkins Jr. | Director |  |

---

## Exhibit 5.1

**Exhibit 5.1**![LOGO](g936331g0625030307499.jpg)

June 27, 2025

QuidelOrtho Corporation

9975 Summers Ridge Road

San Diego, California 92121

Re: *QuidelOrtho Corporation Second Amended and Restated 2018 Equity Incentive Plan*

Ladies and Gentlemen:

We have examined the Registration Statement on Form S-8 (the "Registration Statement") of QuidelOrtho Corporation, a Delaware corporation (the "Company"), to be filed with the Securities and Exchange Commission (the "Commission") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), in connection with the offering by the Company of up to 6,200,000 additional shares of the Company's common stock, par value $0.001 per share (the "Shares"). The Shares subject to the Registration Statement are to be issued under the QuidelOrtho Corporation Second Amended and Restated 2018 Equity Incentive Plan (the "Plan").

In arriving at the opinion expressed below, we have examined originals, or copies certified or otherwise identified to our satisfaction as being true and complete copies of the originals, of such documents, corporate records, certificates of officers of the Company and of public officials and other instruments as we have deemed necessary or advisable to enable us to render the opinion set forth below. In our examination, we have assumed without independent investigation the genuineness of all signatures, the legal capacity and competency of all natural persons, the authenticity of all documents submitted to us as originals and the conformity to original documents of all documents submitted to us as copies. As to any facts material to this opinion, we have relied to the extent we deemed appropriate and without independent investigation upon statements and representations of officers and other representatives of the Company and others. We have also assumed that there are no agreements or understandings between or among the Company and any participants in the Plan that would expand, modify or otherwise affect the terms of the Plan or the respective rights or obligations of the participants thereunder.

Based upon the foregoing, and subject to the assumptions, exceptions, qualifications and limitations set forth herein, we are of the opinion that the Shares, when issued against payment therefor in accordance with the terms set forth in the Plan as set forth in the Registration Statement, will be validly issued, fully paid and non-assessable.

We render no opinion herein as to matters involving the laws of any jurisdiction other than the Delaware General Corporation Law (the "DGCL"). We are not admitted to practice in the State of Delaware; however, we are generally familiar with the DGCL as currently in effect and have made such inquiries as we consider necessary to render the opinions above. This opinion is limited to the effect of the current state of the DGCL and the facts as they currently exist. We assume no obligation to revise or supplement this opinion in the event of future changes in such law or the interpretations thereof or such facts.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving this consent, we do not thereby admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the Rules and Regulations of the Commission.

---

| |
|:---|
| Very truly yours, |
| /s/ Gibson, Dunn & Crutcher LLP |

---

**Gibson, Dunn & Crutcher LLP** 

2000 Ave of the Stars Suite 1200N \| Los Angeles, CA 90067-4700 \| T: 310.552.8500 \| gibsondunn.com

## Exhibit 23.2

**Exhibit 23.2** 

**Consent of Independent Registered Public Accounting Firm** 

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the QuidelOrtho Corporation Second Amended and Restated 2018 Equity Incentive Plan of QuidelOrtho Corporation of our reports dated February 27, 2025, with respect to the consolidated financial statements of QuidelOrtho Corporation, and the effectiveness of internal control over financial reporting of QuidelOrtho Corporation, included in its Annual Report (Form 10-K) for the year ended December 29, 2024, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Diego, California

June 26, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'? EX-FILING FEES

---

| |
|:---|
| **Calculation of Filing Fee Tables**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**S-8**  |
| &nbsp;&nbsp;&nbsp;&nbsp;**QuidelOrtho Corp**  |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **Security Type**  | **Security Class Title**  | **Fee Calculation Rule**  | **Amount Registered**  | **Proposed Maximum Offering Price Per Unit**  | **Maximum Aggregate Offering Price**  | **Fee Rate**  | **Amount of Registration Fee**  |
| 1 | Equity | Common stock, par value $0.001 per share ("Common Stock"), to be issued under the QuidelOrtho Corporation Second Amended and Restated 2018 Equity Incentive Plan | 457(a) | 6200000 | $27.47 | $170314000.00 | 0.0001531 | $26075.07 |
| Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: | Total Offering Amounts: |  | $170314000.00  |  | $26075.07  |
| Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  | Total Fee Offsets:  |  |  |  | $0.00  |
| Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  | Net Fee Due:  |  |  |  | $26075.07  |

---

 **Offering Note** <br>

<sup>1</sup> Pursuant to Rule 416 of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement on Form S-8 also includes additional shares of Common Stock in respect of the securities identified in the above table that may become issuable as a result of adjustments for stock splits, stock dividends and similar transactions pursuant to the terms of the QuidelOrtho Corporation Second Amended and Restated 2018 Equity Incentive Plan. Estimated solely for purposes of calculating the registration fee, pursuant to paragraphs (c) and (h) of Rule 457 under the Securities Act, on the basis of the average of the high and low sale prices of the shares of Common Stock of QuidelOrtho Corporation on the Nasdaq Stock Market on June 23, 2025, within five business days prior to filing.